Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 41, 2016, Pages E6145-E6152

  Kaye, Joel ^a   Piryatinsky, Victor ^a   Birnberg, Tal ^a   Hingaly, Tal ^a   Raymond, Emanuel ^a   Kashi, Rina ^a   Amit Romach, Einat ^a   Caballero, Ignacio S ^b   Towfic, Fadi ^b   Ator, Mark A ^a   Rubinstein, Efrat ^a   Laifenfeld, Daphna ^a   Orbach, Aric ^a   Shinar, Doron ^a   Marantz, Yael ^a   Grossman, Iris ^a   Knappertz, Volker ^a   Hayden, Michael R ^a   Laufer, Ralph ^a  

^a TEVA PHARMACEUTICALS   (Israel)

^b Immuneering Corporation   (United States)

Author keywords

Aryl hydrocarbon receptor; EAE; Laquinimod

Indexed keywords

3 METHYLCHOLANTHRENE; AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; INTERLEUKIN 17; INTERLEUKIN 22; LAQUINIMOD; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OMEPRAZOLE; QUINOLONE DERIVATIVE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; LIVER CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PARALYSIS; PRIORITY JOURNAL; SPLEEN CELL; AGONISTS; ANIMAL; DRUG EFFECTS; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

ANIMALS; CYTOCHROME P-450 CYP1A1; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; IMMUNE SYSTEM; MICE; MICE, KNOCKOUT; QUINOLONES; RECEPTORS, ARYL HYDROCARBON; T-LYMPHOCYTES; TRANSCRIPTOME;

EID: 84991503343     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1607843113     Document Type: Article

References (51)

1. Comi G, et al.; ALLEGRO Study Group (2012) Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 366(11):1000-1009.
2. Filippi M, et al.; ALLEGRO Study Group (2014) Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 85(8):851-858.
3. Vollmer TL, et al.; BRAVO Study Group (2014) A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261(4):773-783.
4. Wegner C, et al. (2010) Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 227(1-2):133-143.
5. Aharoni R, et al. (2012) Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 251(1-2):14-24.
6. Mishra MK, Wang J, Silva C, Mack M, Yong VW (2012) Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am J Pathol 181(2):642-651.
7. Schulze-Topphoff U, et al. (2012) Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS One 7(3):e33797.
8. Thone J, et al. (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180(1):267-274.
9. Jolivel V, et al. (2013) Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136(Pt 4):1048-1066.
10. Ruffini F, et al. (2013) Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis. Mult Scler 19(8):1084-1094.
11. Moore S, et al. (2013) Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis. Brain Behav 3(6):664-682.
12. Mishra MK, et al. (2014) Laquinimod reduces neuroaxonal injury through inhibiting microglial activation. Ann Clin Transl Neurol 1(6):409-422.
13. Zou LP, et al. (2002) Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology 42(5):731-739.
14. Pitarokoili K, et al. (2014) Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 274(1-2):38-45.
15. Lourenco EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ (2014) Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol 66(3):674-685.
16. Sun J, et al. (2015) Laquinimod ameliorates spontaneous colitis in interleukin-10-gene-deficient mice with improved barrier function. Int Immunopharmacol 29(2):423-432.
17. Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U (2014) Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 262(Pt A):66-71.
18. Hu W, Sorrentino C, Denison MS, Kolaja K, Fielden MR (2007) Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol Pharmacol 71(6):1475-1486.
19. MacPherson L, et al. (2014) Aryl hydrocarbon receptor repressor and TiPARP (ARTD14) use similar, but also distinct mechanisms to repress aryl hydrocarbon receptor signaling. Int J Mol Sci 15(5):7939-7957.
20. Boutros PC, et al. (2011) Hepatic transcriptomic responses to TCDD in dioxin-sensitive and dioxin-resistant rats during the onset of toxicity. Toxicol Appl Pharmacol 251(2):119-129.
21. Jaronen M, Quintana FJ (2014) Immunological relevance of the coevolution of IDO1 and AHR. Front Immunol 5:5-1.
22. Nguyen NT, et al. (2014) Aryl hydrocarbon receptor and kynurenine: Recent advances in autoimmune disease research. Front Immunol 5:5-1.
23. Hao N, et al. (2012) Xenobiotics and loss of cell adhesion drive distinct transcriptional outcomes by aryl hydrocarbon receptor signaling. Mol Pharmacol 82(6):1082-1093.
24. Quintana FJ, et al. (2010) An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 107(48):20768-20773.
25. Quintana FJ, et al. (2008) Control of T (reg) and T (H) 17 cell differentiation by the aryl hydrocarbon receptor. Nature 453(7191):65-71.
26. Kimura A, Naka T, Nohara K, Fujii-Kuriyama Y, Kishimoto T (2008) Aryl hydrocarbon receptor regulates Stat1 activation and participates in the development of Th17 cells. Proc Natl Acad Sci USA 105(28):9721-9726.
27. Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B (2013) Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLoS One 8(11):e79819.
28. Hayes MD, Ovcinnikovs V, Smith AG, Kimber I, Dearman RJ (2014) The aryl hydrocarbon receptor: Differential contribution to T helper 17 and T cytotoxic 17 cell development. PLoS One 9(9):e106955.
29. Quintana FJ (2013) Regulation of central nervous system autoimmunity by the aryl hydrocarbon receptor. Semin Immunopathol 35(6):627-635.
30. Pot C (2012) Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med Wkly 142:w13592.
31. Apetoh L, et al. (2010) The aryl hydrocarbon receptor interacts with c-Maf to promote the differentiation of type 1 regulatory T cells induced by IL-27. Nat Immunol 11(9):854-861.
32. Gandhi R, et al. (2010) Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. Nat Immunol 11(9):846-853.
33. Wu HY, et al. (2011) In vivo induction of Tr1 cells via mucosal dendritic cells and AHR signaling. PLoS One 6(8):e23618.
34. Mascanfroni ID, et al. (2015) Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med 21(6):638-646.
35. Denison MS, Soshilov AA, He G, DeGroot DE, Zhao B (2011) Exactly the same but different: Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. Toxicol Sci 124(1):1-22.
36. Bruck W, et al. (2012) Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 124(3):411-424.
37. Ruby CE, Leid M, Kerkvliet NI (2002) 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected. Mol Pharmacol 62(3):722-728.
38. Vogel CF, et al. (2014) Cross-talk between aryl hydrocarbon receptor and the inflammatory response: A role for nuclear factor-κB. J Biol Chem 289(3):1866-1875.
39. Rothhammer V, et al. (2016) Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med 22(6):586-597.
40. Esser C, Rannug A (2015) The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev 67(2):259-279.
41. Nguyen NT, Hanieh H, Nakahama T, Kishimoto T (2013) The roles of aryl hydrocarbon receptor in immune responses. Int Immunol 25(6):335-343.
42. Quintana FJ, Sherr DH (2013) Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev 65(4):1148-1161.
43. Cella M, Colonna M (2015) Aryl hydrocarbon receptor: Linking environment to immunity. Semin Immunol 27(5):310-314.
44. Zhou L (2016) AHR function in lymphocytes: Emerging concepts. Trends Immunol 37(1):17-31.
45. Dorgham K, et al. (2015) Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. Eur J Immunol 45(11):3174-3187.
46. Lamas B, et al. (2016) CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. Nat Med 22(6):598-605.
47. Dobin A, et al. (2013) STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29(1):15-21.
48. Liao Y, Smyth GK, Shi W (2014) featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7):923-930.
49. Harrow J, et al. (2012) GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 22(9):1760-1774.
50. Law CW, Chen Y, Shi W, Smyth GK (2014) voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 15(2):R29.
51. Ritchie ME, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47.